The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.

Marzano, A.V., Genovese, G., Casazza, G., Moltrasio, C., Dapavo, P., Micali, G., et al. (2020). Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study. BRITISH JOURNAL OF DERMATOLOGY [10.1111/bjd.18983].

Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study

Sirna, R;Patrizi, A;Dini, V;Bongiorno, M R;
2020-01-01

Abstract

The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
Marzano, A.V., Genovese, G., Casazza, G., Moltrasio, C., Dapavo, P., Micali, G., et al. (2020). Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study. BRITISH JOURNAL OF DERMATOLOGY [10.1111/bjd.18983].
File in questo prodotto:
File Dimensione Formato  
evidence for a window.pdf

Solo gestori archvio

Tipologia: Pre-print
Dimensione 1.56 MB
Formato Adobe PDF
1.56 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/401854
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 45
social impact